As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
6 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:
6 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast:
Apr '25 |
+/-
%
|
||
Revenue | 18 18 |
0%
0%
|
|
Gross Profit | 9.85 9.85 |
12%
12%
|
|
EBITDA | -7.58 -7.58 |
6%
6%
|
EBIT (Operating Income) EBIT | -9 -9 |
12%
12%
|
Net Profit | -22 -22 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
Head office | Canada |
CEO | Jennifer Bath |
Employees | 87 |
Founded | 1983 |
Website | www.ipatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.